eTable 3. Efficacy of mitoxantrone in patients with concomitant IS versus others at the 96th week of follow-up

	Patients with concomitant IS between the M12 the M12 of MiTX and the 96th week of follow-up		
Characteristic	**No**, n = 76	**yes**, n = 10	**p-value**
Antibody			0.222
NMOSD-DN	19 (25.0%)	1 (10.0%)	
NMOSD-AQP4+	52 (68.4%)	7 (70.0%)	
MOGAD	5 (6.6%)	2 (20.0%)	
Time from the first attack to MiTX (months)			0.034
Median (IQR)	11.0 (3.0 - 56.3)	2.0 (1.3 - 5.3)	
Total relapse count before MiTX			0.234
1	25 (32.9%)	6 (60.0%)	
2	16 (21.1%)	2 (20.0%)	
≥ 3	35 (46.1%)	2 (20.0%)	
MiTX from the first attack	25 (32.9%)	6 (60.0%)	0.158
First endpoint			
First relapse during the 96-week follow-up	23 (30.3%)	2 (20.0%)	0.717
Treatment efficacy†			0.699
Complete success	53 (69.7%)	8 (80.0%)	
Incomplete achievement	6 (7.9%)	0 (0.0%)	
Partial failure	8 (10.5%)	0 (0.0%)	
Complete failure	9 (11.8%)	2 (20.0%)	
Secondary endpoints			
Time to first relapse during the 96-week of follow-up (weeks)	37.0 (18.0 - 58.5)	15.5 (13.8 - 17.3)	0.229
ARR the year before MiTX (mean, +/- SD)	0.86 +/- 0.56	0.75 +/- 0.49	0.462
ARR T96 (mean, +/- SD)	0.33 +/- 0.65	0.18 +/- 0.39	0.517
Reduction in ARR from T0 to T96	61.1 +/- 77.6	63.2 +/- 77.6	0.650
EDSS T0 (mean, +/- SD)	5.04 +/- 2.35	4.25 +/- 2.54	0.241
EDSS T96 (mean, +/- SD)	4.28 +/- 2.50	3.95 +/- 3.08	0.710
EDSS severity at T0			0.535
Minor [0;3.5]	30 (39.5%)	6 (60.0%)	
Moderate [4;5.5]	12 (15.8%)	1 (10.0%)	
Severe [6;10]	34 (44.7%)	3 (30.0%)	
EDSS severity at T96			0.901
Minor [0;3.5]	35 (46.1%)	6 (60.0%)	
Moderate [4;5.5]	12 (15.8%)	1 (10.0%)	
Severe [6;10]	29 (38.2%)	3 (30.0%)	

Abbreviations: AQP4+, positive anti-aquaporin-4 antibody; ARR, annualized relapse rate; DN, double-seronegative; EDSS, Expanded Disability Status Scale; IS, immunosuppressant; MiTX, mitoxantrone; M12, the sixth infusion of mitoxantrone; MOGAD, myelin oligodendrocyte glycoprotein antibody-associated disease; NMOSD, neuromyelitis optica spectrum disorder; T0, initiation of mitoxantrone; T96: at the 96th week of follow-up.

†Complete success of MiTX: patients relapse-free at 96 weeks follow-up; incomplete achievement: patients had a relapse while having a decrease in ARR at 96 weeks follow-up; partial failure: patients had a relapse without modification in ARR at 96 weeks follow-up; complete failure: patients had a relapse while having an increase in ARR at 96 weeks of follow-up.